The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

Ladies and gentlemen, thank you for standing-by, and welcome to the Lilly Q3 2024 Earnings Call. [Operator Instructions] I ...

Drops for Big Tech companies including Microsoft and Facebook's parent company Meta Platforms led Wall Street lower.

And in July, the FDA greenlit Lilly's Alzheimer's disease treatment, Kisunla. Sales have been limited but a recent approval in Japan could make it a significant growth driver in the quarters ahead.

Add articles to your saved list and come back to them any time. The Australian sharemarket has extended its losses on ...

Asian shares are mostly declining amid uncertainty ahead of the United States presidential election next week.

Eli Lilly reported weaker results for the latest quarter than analysts ... In stock markets abroad, indexes were mostly lower ...

ASX 200 futures are trading 14 points lower, down 0.17%, as of 8:30 am AEDT. Major US benchmarks fell overnight amid a mixed ...

The S&P 500 slipped 0.3% after drifting between small gains and losses several times, though it’s still near its all-time ...

Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two ...